FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4285405642> ?p ?o ?g. }

• W4285405642 endingPage "351" @default.
• W4285405642 startingPage "345" @default.
• W4285405642 abstract "At present, GATA binding protein 3 (GATA-3) is the most frequently used diagnostic immunohistochemical (IHC) marker for breast carcinoma (BC). However, it is not specific and has very low sensitivity for triple-negative BC (TNBC). SRY-box transcription factor 10 (SOX-10) and trichorhinophalangeal syndrome type 1 (TRPS-1) have been suggested for inclusion in the diagnostic workup of TNBC. TRPS-1 has not been established in cytology specimens as a diagnostic IHC marker for metastatic BC (MBC). Hence, in the present study we evaluated the utility of TRPS-1 in diagnosing MBC in cytology specimens.MBC cases diagnosed on cytology specimens from January to October 2020 were included in the present study. Only cases with hormonal status available and ≥20 tumor cells on cell blocks were included in the study. The cell blocks were assessed for TRPS-1, GATA-3, and SOX-10 IHC marker positivity (intensity and percentage of tumor cells). The results were correlated with the specimen type (fine needle aspiration [FNA] versus body fluid) and various BC prognostic subgroups.We analyzed 61 cases, including 33 body fluid and 28 FNA (13 lymph node, 10 bone, 2 liver, 2 soft tissue, and 1 lung) specimens. TRPS-1 had 97.2% positivity in ER/PR+ (estrogen receptor/progesterone receptor-positive) MBC compared with GATA-3, which had 100% positivity in the same group. TRPS-1 showed high positivity in 35 of 37 cases (94.6%) and intermediate positivity in 1 (2.6%) and was negative/low positive in 1 case (2.7%). In contrast, GATA-3 showed high positivity for all 37 cases (100%). SOX-10 showed positivity in only 1 of 37 cases (2.7%), with intermediate positivity. In the HER2+ (human epidermal growth factor receptor 2-positive) group, TRPS-1 showed high positivity in 5 of 7 cases (71.4%), intermediate positivity in 1 case (14.3%), and negativity in 1 case (14.3%). However, GATA-3 showed high positivity in 6 of 7 cases (85.7%) and negative/low positivity in 1 case (14.3%). SOX-10 was negative in all 7 cases. In TNBC, TRPS-1 showed high positivity in 16 of 17 cases (94%) and intermediate positivity in 1 (5.9%), and GATA-3 showed high positivity in 9 (53%), intermediate positivity in 2 (11.8%), and low positive/negative in 6 of the 17 cases (35.3%). TRPS-1 expression was significantly higher than GATA-3 expression for the number of positive cases (P = 0.07), mean percentage of positive tumor cells (P = 0.005), and intensity of reactivity (P = 0.005). SOX-10 expression was present in only 5 of 17 cases (29%), with a mean percentage of positivity in the tumor cells of 26.5% and intensity of 0.8. No differences were found in the IHC results between the different specimen types (FNA versus fluid) in any group.TRPS-1 is a highly sensitive new diagnostic IHC marker for breast carcinoma, with a similar positivity rate in ER/PR+ and HER2+ BC compared with GATA-3 and a higher positivity rate than GATA-3 and SOX-10 in TNBC in cytology specimens. In particular, when only a few clusters of tumor cells are present on the cell block, TRPS-1 can be highly useful, because its mean percentage of positive tumor cells and intensity are higher than those of other IHC markers." @default.
• W4285405642 created "2022-07-14" @default.
• W4285405642 creator A5019474394 @default.
• W4285405642 creator A5020237290 @default.
• W4285405642 creator A5028203396 @default.
• W4285405642 creator A5031826756 @default.
• W4285405642 creator A5031938967 @default.
• W4285405642 creator A5037004752 @default.
• W4285405642 creator A5067058768 @default.
• W4285405642 creator A5082196933 @default.
• W4285405642 date "2022-11-01" @default.
• W4285405642 modified "2023-10-16" @default.
• W4285405642 title "Utility of TRPS-1 immunohistochemistry in diagnosis of metastatic breast carcinoma in cytology specimens" @default.
• W4285405642 cites W1592418509 @default.
• W4285405642 cites W2005412280 @default.
• W4285405642 cites W2027528241 @default.
• W4285405642 cites W2082331212 @default.
• W4285405642 cites W2093947564 @default.
• W4285405642 cites W2094034334 @default.
• W4285405642 cites W2100072610 @default.
• W4285405642 cites W2114978011 @default.
• W4285405642 cites W2181187771 @default.
• W4285405642 cites W2328039719 @default.
• W4285405642 cites W2596771550 @default.
• W4285405642 cites W2605034387 @default.
• W4285405642 cites W2625310896 @default.
• W4285405642 cites W2734989536 @default.
• W4285405642 cites W2747428770 @default.
• W4285405642 cites W2762614963 @default.
• W4285405642 cites W2790243532 @default.
• W4285405642 cites W2806837663 @default.
• W4285405642 cites W2909149433 @default.
• W4285405642 cites W3016270696 @default.
• W4285405642 cites W3090719330 @default.
• W4285405642 cites W3128646645 @default.
• W4285405642 cites W4206279506 @default.
• W4285405642 cites W4223535166 @default.
• W4285405642 doi "https://doi.org/10.1016/j.jasc.2022.06.007" @default.
• W4285405642 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36055933" @default.
• W4285405642 hasPublicationYear "2022" @default.
• W4285405642 type Work @default.
• W4285405642 citedByCount "9" @default.
• W4285405642 countsByYear W42854056422022 @default.
• W4285405642 countsByYear W42854056422023 @default.
• W4285405642 crossrefType "journal-article" @default.
• W4285405642 hasAuthorship W4285405642A5019474394 @default.
• W4285405642 hasAuthorship W4285405642A5020237290 @default.
• W4285405642 hasAuthorship W4285405642A5028203396 @default.
• W4285405642 hasAuthorship W4285405642A5031826756 @default.
• W4285405642 hasAuthorship W4285405642A5031938967 @default.
• W4285405642 hasAuthorship W4285405642A5037004752 @default.
• W4285405642 hasAuthorship W4285405642A5067058768 @default.
• W4285405642 hasAuthorship W4285405642A5082196933 @default.
• W4285405642 hasConcept C121608353 @default.
• W4285405642 hasConcept C126322002 @default.
• W4285405642 hasConcept C142724271 @default.
• W4285405642 hasConcept C143998085 @default.
• W4285405642 hasConcept C18823058 @default.
• W4285405642 hasConcept C204232928 @default.
• W4285405642 hasConcept C2780849966 @default.
• W4285405642 hasConcept C530470458 @default.
• W4285405642 hasConcept C71924100 @default.
• W4285405642 hasConcept C84606932 @default.
• W4285405642 hasConcept C98717036 @default.
• W4285405642 hasConceptScore W4285405642C121608353 @default.
• W4285405642 hasConceptScore W4285405642C126322002 @default.
• W4285405642 hasConceptScore W4285405642C142724271 @default.
• W4285405642 hasConceptScore W4285405642C143998085 @default.
• W4285405642 hasConceptScore W4285405642C18823058 @default.
• W4285405642 hasConceptScore W4285405642C204232928 @default.
• W4285405642 hasConceptScore W4285405642C2780849966 @default.
• W4285405642 hasConceptScore W4285405642C530470458 @default.
• W4285405642 hasConceptScore W4285405642C71924100 @default.
• W4285405642 hasConceptScore W4285405642C84606932 @default.
• W4285405642 hasConceptScore W4285405642C98717036 @default.
• W4285405642 hasIssue "6" @default.
• W4285405642 hasLocation W42854056421 @default.
• W4285405642 hasLocation W42854056422 @default.
• W4285405642 hasOpenAccess W4285405642 @default.
• W4285405642 hasPrimaryLocation W42854056421 @default.
• W4285405642 hasRelatedWork W2133282979 @default.
• W4285405642 hasRelatedWork W2134192859 @default.
• W4285405642 hasRelatedWork W2228116816 @default.
• W4285405642 hasRelatedWork W2384240029 @default.
• W4285405642 hasRelatedWork W2385526873 @default.
• W4285405642 hasRelatedWork W2410151961 @default.
• W4285405642 hasRelatedWork W2414141389 @default.
• W4285405642 hasRelatedWork W2470372846 @default.
• W4285405642 hasRelatedWork W2485478516 @default.
• W4285405642 hasRelatedWork W3031413756 @default.
• W4285405642 hasVolume "11" @default.
• W4285405642 isParatext "false" @default.
• W4285405642 isRetracted "false" @default.
• W4285405642 workType "article" @default.